Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.
Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.
复制标题
如（89）ZR-利妥昔单抗免疫-PET所预测的CD20+ B细胞淋巴瘤中（90）Y-利妥昔单抗在CD20+ B细胞淋巴瘤中的肿瘤靶向和辐射剂量：未经标记的Rituximab对预加载的影响。
DOI：
10.1007/s00259-015-3025-6
复制
发表时间：
2015-07
影响因子：
9.1
通讯作者：
Bron, Dominique
中科院分区：
文献类型：
--
作者：
Muylle, Kristoff;Flamen, Patrick;Vugts, Danielle J.;Guiot, Thomas;Ghanem, Ghanem;Meuleman, Nathalie;Bourgeois, Pierre;Vanderlinden, Bruno;van Dongen, Guus A. M. S.;Everaert, Hendrik;Vaes, Melanie;Bron, Dominique
关键词：
使用免疫PET/CT比较不加和加未标记利妥昔单抗预载的89 Zr标记利妥昔单抗的分布，以评估未标记利妥昔单抗预载对CD 20 + B细胞淋巴瘤中后续90 Y标记利妥昔单抗放射免疫治疗的肿瘤靶向和辐射剂量的影响。前瞻性入组了5例CD 20 + B细胞淋巴瘤和疾病进展患者。所有患者均经历三个研究阶段：初始剂量测定阶段，基线89 Zr-利妥昔单抗PET/CT成像，无冷预负荷，3周后，第二剂量测定阶段，给予标准预负荷（250 mg/m2）未标记利妥昔单抗，随后注射89 Zr-利妥昔单抗，1周后，治疗阶段，给予未标记利妥昔单抗，随后注射90 Y-利妥昔单抗。评估PET/CT成像和器官和病变的示踪剂摄取。在冷利妥昔单抗预负荷的情况下，所有患者的90 Y-利妥昔单抗的计算全身剂量相似（平均值为0.87 mSv/MBq，范围为0.82-0.99 mSv/MBq）。在没有前负荷的情况下，在两名保留循环CD 20 + B细胞的患者中观察到全身剂量增加59%和87%。这种辐射剂量的增加主要是由于在没有预负荷的情况下脾脏的剂量增加了12.4倍至15倍。在其他3例B细胞耗竭患者中，未观察到全身剂量的显著变化。在没有前负荷的情况下，在B细胞耗竭的患者中观察到持续较高的肿瘤摄取。未标记利妥昔单抗的标准前负荷给药损害了大多数适合放射免疫治疗的患者（即先前用含利妥昔单抗的治疗方案治疗的患者）的放射缀合物肿瘤靶向。这种常见的做法可能需要重新考虑和进一步评估，因为这种高前负荷的基本原理起源于“prerituximab时代”。临床试验申请：CTA 2011-005474-38试验登记：EudraCT本文的在线版本（doi：10.1007/s 00259 -015-3025-6）包含补充材料，可供授权用户使用。
To compare using immuno-PET/CT the distribution of 89Zr-labelled rituximab without and with a preload of unlabelled rituximab to assess the impact of preloading with unlabelled rituximab on tumour targeting and radiation dose of subsequent radioimmunotherapy with 90Y-labelled rituximab in CD20+ B-cell lymphoma. Five patients with CD20+ B-cell lymphoma and progressive disease were prospectively enrolled. All patients underwent three study phases: initial dosimetric phase with baseline 89Zr-rituximab PET/CT imaging without a cold preload, followed 3 weeks later by a second dosimetric phase with administration of a standard preload (250 mg/m2) of unlabelled rituximab followed by injection of 89Zr-rituximab, and a therapeutic phase 1 week later with administration of unlabelled rituximab followed by 90Y-rituximab. PET/CT imaging and tracer uptake by organs and lesions were assessed. With a cold rituximab preload, the calculated whole-body dose of 90Y-rituximab was similar (mean 0.87 mSv/MBq, range 0.82–0.99 mSv/MBq) in all patients. Without a preload, an increase in whole-body dose of 59 % and 87 % was noted in two patients with preserved circulating CD20+ B cells. This increase in radiation dose was primarily due to a 12.4-fold to 15-fold higher dose to the spleen without a preload. No significant change in whole-body dose was noted in the three other patients with B-cell depletion. Without a preload, consistently higher tumour uptake was noticed in patients with B-cell depletion. Administration of the standard preload of unlabelled rituximab impairs radioconjugate tumour targeting in the majority of patients eligible for radioimmunotherapy, that is patients previously treated with rituximab-containing therapeutic regimens. This common practice may need to be reconsidered and further evaluated as the rationale for this high preload has its origin in the “prerituximab era”. Clinical Trial Application: CTA 2011-005474-38 Trial Registry: EudraCT The online version of this article (doi:10.1007/s00259-015-3025-6) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
158.5
作者：
KAMINSKI, MS;ZASADNY, KR;WAHL, RL
通讯作者：
WAHL, RL
影响因子：
20.3
作者：
Hiddemann, W;Kneba, M;Unterhalt, M
通讯作者：
Unterhalt, M
影响因子：
20.3
作者：
Illidge, Tim M.;Bayne, Mike;Johnson, Peter W. M.
通讯作者：
Johnson, Peter W. M.
影响因子：
158.5
作者：
Kaminski, MS;Tuck, M;Wahl, RL
通讯作者：
Wahl, RL
影响因子：
45.3
作者：
Illidge, Tim M.;Mayes, Sam;Morschhauser, Franck
通讯作者：
Morschhauser, Franck